Advances in imaging gene-directed enzyme prodrug therapy

Area of Science:

• Oncology
• Gene Therapy
• Molecular Imaging

Background:

• Gene-directed enzyme prodrug therapy (GDEPT) is an anticancer strategy using foreign genes to activate prodrugs selectively in tumor cells.
• This approach offers a promising alternative to conventional chemotherapy by targeting tumor cells for death.

Purpose of the Study:

• To review promising suicide gene/prodrug combinations for cancer therapy.
• To discuss the role of molecular imaging in improving GDEPT strategies.
• To highlight advancements in imaging modalities for preclinical and clinical translation.

Main Methods:

• Review of three key suicide gene/prodrug systems: HSV-TK/GCV, CD/5-FC, and NTR/CB1954.
• Discussion of molecular imaging techniques including Optical, MRI, PET, and SPECT.
• Examination of reporter genes and imageable probes for monitoring therapeutic gene delivery and expression.

Main Results:

• Identified HSV-TK/GCV, CD/5-FC, and NTR/CB1954 as highly promising gene/prodrug combinations.
• Demonstrated the utility of noninvasive imaging for assessing vector dose, tumor selectivity, transgene expression, and biodistribution.
• Highlighted the potential of advanced imaging to bridge the gap between preclinical research and clinical application.

Conclusions:

• GDEPT represents a significant advancement in cancer treatment, offering targeted tumor cell death.
• Molecular imaging is crucial for optimizing GDEPT by providing real-time monitoring of therapeutic efficacy.
• Integrating imaging technologies will accelerate the clinical translation of novel prodrug cancer therapies.